Prasad | Vaccine Development | Buch | 978-1-78801-877-7 | sack.de

Buch, Englisch, Band 3, 322 Seiten, Format (B × H): 163 mm x 240 mm, Gewicht: 640 g

Reihe: Drug Development and Pharmaceutical Science

Prasad

Vaccine Development


From Concept to Clinic

Buch, Englisch, Band 3, 322 Seiten, Format (B × H): 163 mm x 240 mm, Gewicht: 640 g

Reihe: Drug Development and Pharmaceutical Science

ISBN: 978-1-78801-877-7
Verlag: RSC Publishing

Vaccine development is a complex and time consuming process that differs from the development of conventional pharmaceuticals. Primarily, vaccines are intended for use in healthy individuals as a preventative measure, requiring a long and rigorous process of research and many years of testing and development prior to clinical trials and regulatory approval. The average time for the development of vaccines to clinical is 12 to 15 years. Vaccine Development: From Concept to Clinic is a detailed overview of the development of new vaccines, covering the entire process and addresses all classes of vaccines from a processing, development and regulatory viewpoint. Utilising successful case studies the book will provide insight to the issues scientists face when producing a vaccine, the steps involved and will serve as an ideal reference tool regarding state-of-the-art vaccine development. This book is an ideal companion for any researchers working in vaccine discovery and development or with an interest in the field.
Prasad Vaccine Development jetzt bestellen!

Autoren/Hrsg.

Prasad, A Krishna

Fachgebiete

Weitere Infos & Material

Vaccine Development: From Concept to Clinic; Pre-clinical Safety Assessment Considerations for Vaccine Development; Clinical Trials in the Development of Vaccines for Infectious Diseases; Clinical Trials in Immunotherapeutic Vaccine Development; Pathogenesis and Immunity of SARS-CoV-2 and Vaccination Programs against COVID-19; High Throughput Assays for Clinical Development; Virus-like Particle Based Vaccines: GARDASIL®; Cell Culture-based Influenza Vaccine Development; Conjugate Vaccines: Design and Development Considerations; Vaccine Adjuvants: Mechanisms of Action; Development Considerations for Final Dosage Forms: Mucosal Bacterial Vaccines; Exploiting Glycans in Vaccine Design; The PATH Experience in Vaccine Development Partnerships with Manufacturers from Emerging Markets

Johnson, Matthew
Duke University, USA

HogenEsch, Harm
Purdue University, USA

Prasad, A Krishna
Citranvi LLC., USA

Lockhart, Steve
Pfizer, UK

Rajaram, Raja
Seqirus, UK

Knirsch, Chuck
Pfizer, USA

Cooper, David
Pfizer, USA

Gunawardana, Abey
Merck, USA

Harris, Shannon
Seqirus, USA

Prasad, A Krishna
Citranvi LLC., USA

Patel, Amish
Emergent Biosolutions, USA

Abraham, Dicky
Merck, USA

Rohde, Cynthia
Pfizer, USA

Ergenzinger, Edward
Fisher-Broyles, USA

Khandke, Lakshmi
PATH, USA

Zablackis, Earl
Sanofi, USA

Hausdorff, William
PATH, USA

Kanevsky, Isis
Pfizer, USA

Gao, Guang
PATH, China

Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.